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ABSTRACT 
BACKGROUND: Central Core Disease (CCD) is a congenital myopathy often resulting from 
a mutation in RYR1 gene. Mutations in RyR1 can increase or decrease channel activity, or 
induce a reduction in the amount of protein. The consequences of a single mutation are 
sometimes multiple and the analysis of the functional effects is complex. 
OBJECTIVE: The consequences of the p.Y4864H mutation identified in a CCD patient have 
been studied regarding both RyR1 function and amount. 
METHODS: The amount of RyR1 in human and mouse muscles was evaluated using qRT-
PCR and quantitative Western blot, and calcium release was studied using calcium imaging 
on primary cultures. The results were compared between human and mouse. 
RESULTS: The p.Y4864H mutation induced an alteration of calcium release, and in addition 
was associated to a reduction in the amount of RyR1 in the patient’s muscle. This suggests 
two possible pathophysiological mechanisms: the alteration of calcium release could result 
from a modification of the channel properties of RyR1 or from a RyR1 reduction. In order to 
discriminate between the two hypotheses, we used the heterozygous RyR1 knockout   
(RyR1
+/-
) mouse model showing a comparable RyR1 protein reduction. No reduction in 
calcium release was observed in primary muscle culture from these mice, and no muscle 
weakness was measured. 
CONCLUSIONS: Because the reduction in the amount of RyR1 protein has no functional 
consequences in the murine model, the muscle weakness observed in the patient is most likely 
the result of a modification of the calcium channel function of RyR1 due to the p.Y4864H 
mutation. 
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INTRODUCTION 
The sarcoplasmic reticulum (SR) calcium channel ryanodine receptor RyR1 is 
encoded by the RYR1 gene (MIM#180901). In association with the voltage gated calcium 
channel dihydropyridine receptor (DHPR) and numerous regulating proteins, they form the 
skeletal muscle calcium release complex responsible for the excitation-contraction coupling 
process in skeletal muscle [1]. 
Mutations in the RYR1 gene have been associated with congenital myopathies such as 
Central Core Disease (CCD; OMIM#117000) [2-4] and Multiminicore Disease (MmD; 
OMIM# 255320) [5-7]. CCD has been named after anatomo-pathological muscle analysis, 
and is characterized by the presence of cores in type 1 muscle fibers, which are large areas of 
abnormal myofibrillar architecture with sarcomeric disorganization and absence of 
mitochondria [2; 8]. CCD presents either an autosomal dominant or a recessive transmission 
pattern. Clinical presentations are heterogeneous ranging from mild phenotype, with moderate 
hypotonia during early childhood, delayed motor abilities, and slowly progressive proximal 
muscle weakness, to severe phenotype, including fetal akinesia, respiratory insufficiency at 
birth and generalized muscle weakness [9-10].  
Dominantly inherited RYR1 mutations have been extensively studied to identify the 
pathophysiological mechanism. Two mechanisms have been proposed so far: either a gain of 
function of RyR1 (hyperactivity) leading to a calcium leak or a loss of RyR1 function with 
impaired calcium conductance [11-14]. 
It has been observed that recessive mutations in RYR1 can also result in a reduction in 
the amount of protein [15-16], which leads to muscle weakness and altered calcium release 
[17]. In the present work, we studied the pathological mechanisms leading to a moderate CCD 
in which a missense dominant mutation in RyR1 was associated with a 25% decrease in the 
amount of protein. Until now the effect of such a RyR1 reduction has never been explored. 
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Using an animal model presenting with a similar reduction in the amount of RyR1, we 
showed no alteration of muscle calcium release or of muscle strength. We concluded that the 
consequence of this RyR1 mutation in the patient's muscle was not related to the reduction in 
the amount of protein, but rather to the direct effect of the mutation on the channel function. 
These results provide new insights into the pathogenesis of RYR1-related myopathies with 
RyR1 deficiency. 
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MATERIALS AND METHODS 
Ethics Statement 
Investigations on patient material were performed after signature of an informed consent 
according to the French regulation and have received approval from the local ethical 
committee (Comité de Protection des Personnes-Sud-Est, France). All procedures using 
animals were approved by the Institutional Ethics Committee and followed the guidelines of 
the National Research Council Guide for the care and use of laboratory animals. 
 
Muscle biopsy and IVCT 
Part of the muscle biopsy realized in vastus lateralis has been directly processed for in vitro 
contracture test (IVCT) according to the European Malignant Hyperthermia Group Guidelines 
(http://www.emhg.org/emhg/mh-diagnosis/). Another part was used for cell culture and 
Western blot, and the remaining muscle was frozen in liquid nitrogen cooled isopentane for 
histological and mRNA analyses. 
 
Molecular genetic studies 
RYR1 mutations screening was performed using cDNA obtained after reverse transcription of 
total RNA extracted from muscle biopsy as previously described [2]. The cDNA was 
amplified in overlapping fragments. Sequencing reactions were analyzed on an ABI 3130 
DNA Analyzer (Life Technologies, Saint Aubin, France). The presence of the mutation 
identified in the transcript was confirmed in genomic DNA by direct sequencing of the 
corresponding exon and intron-exon junctions. 
 
Mouse lines 
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RyR1 knock out mice (RyR1
-/-
), heterozygous mice (RyR1
+/-
) and wild type (RyR1
+/+
) were 
obtained by crossing heterozygous Ryr1
tm1Alle
 mice 
(http://www.informatics.jax.org/allele/key/637575). In this mouse line, the insertion of a 
neomycin selection cassette in the KPN site at nt840 in exon10 of the RYR1 gene leads to 
disruption of gene expression [27].  
 
Mouse muscle homogenate preparation 
Skeletal muscles were collected from the hind limbs of adult (6-7 months old) male mice. 
Crude homogenates were prepared by homogenization in 200 mM sucrose, 20 mM HEPES 
(pH 7.4), 0.4 mM CaCl2, 200 µM phenylmethylsulfonyl fluoride, 1 mM diisopropyl 
fluorophosphate, as described previously [18]. Protein concentration was measured using a 
modified Folin assay in presence of SDS.  
 
Quantitative Western blot analysis 
The amount of RyR1 present in muscle samples (20-40µg of muscle homogenate) was 
determined by quantitative Western blot analysis using antibodies directed against RyR1 [19] 
and normalized to the amount of myosin heavy chain as described previously [16]. Briefly, 
after electrophoretic separation on a 5-15% gradient acrylamide gel and electrotransfer to 
Immobilon P (Biorad, Marnes la Coquette, France) during 4h at 0.8A to ensure a complete 
transfer of the loaded proteins, the membrane was incubated with anti-RyR1 antibodies and 
then HRP-labelled secondary antibodies. Variation in protein loading or in muscle protein 
content due to heterogeneity of the sample, e.g. muscle fibrosis, was evaluated as the amount 
of myosin in each lane determined by Coomassie staining of the Immobilon membrane after 
immunorevelation (measured as the surface of the myosin band). The total amount of RyR1 in 
each experiment (total signal on the two or three bands) was thus corrected from the amount 
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of myosin and normalized to the amount of RyR1 present in the control referred as 100%. 
Quantification was also performed using anti-desmin antibody (Dakocytomation, Les Ulis, 
France) for normalization compared to the amount of desmin, and similar results were 
obtained. Signal quantification was performed using a ChemiDoc XRS apparatus (Biorad, 
Marnes la Coquette, France) and the Quantity One software (Biorad).  
 
q RT-PCR 
Human muscle 
Total RNA was extracted from frozen muscle biopsy using TRIzol reagent (Life 
Technologies, Saint Aubin, France) as previously described [16]. First strand cDNA synthesis 
from 500ng total RNA was realized using random priming with the High Capacity cDNA 
Reverse Transcription kit (Life Technologies, Saint Aubin, France). Real time quantification 
of mRNAs of target gene RYR1 and of reference genes (hRPL27 and ACTB) was performed 
with Power SYBR Green PCR Master Mix (Life Technologies, Saint Aubin, France) using a 
STEPONEPLUS (Life Technologies, Saint Aubin, France) detection system. The following 
primers were used (5’→3’):  RYR1_pcr1 forward: CAT GGC TTC GAG ACT CAC AC, 
RYR1_pcr1 reverse: CTC CTG ACC CGT GTG TTC T, RYR1_pcr2 forward: GAC TCA 
CAC GCT GGA GGA G, RYR1_pcr2 reverse: TCC AGA CAT AAG ACT CCT GAC C,  
ACTB forward: CTC CTG AGC GCA AGT ACT CC, ACTB reverse : TGT TTT CTG CGC 
AAG TTA GG, hRPL27 forward : CGC AAA GCT GTC ATC GTG, hRPL27 reverse : GTC 
ACT TTG CGG GGG TAG. The following experimental protocol was used: denaturation 
95°C for 10 min and 40 cycles of 95°C for 15 sec and 60°C for 60 sec. Melting curve analysis 
showed specific melting temperatures.  
Mouse muscle 
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Total RNA from skeletal muscle (tibialis anterior) of 2-month-old WT (RyR1
+/+
) and 
heterozygous (RyR1
+/-
) mice (3 animals in each group) was extracted using TRIzol reagent 
(Life Technologies, Saint Aubin, France) and PureLink RNA Mini Kit (Life Technologies, 
Saint Aubin, France). First strand cDNA was obtained using oligo(dT) primed reverse 
transcription from 500ng of RNA. Real time quantification of mRNAs of target 
gene RYR1 and of reference gene (GAPDH ) was performed by iQ SYBR Green supermix 
(BioRad, Marnes la Coquette, France) using an IQ iCycler (BioRad, Marnes la Coquette, 
France) detection system. The following primers were used (5’→3’):  RYR1, forward - ATG 
ACC GTA GGG CTC CTG GCC GTA G, reverse - GGG TCC TCG ATC TCG TCC CCG 
A; GAPDH forward - GTA TGA CTC CAC TCA CGG CAA A, reverse - TTC CCA TTC 
TCG GCC TTG. The following experimental protocol was used: denaturation 95°C for 3 min 
and 40 cycles of 95°C for 10 sec and 55°C for 45 sec. Melting curve analysis showed specific 
melting temperatures.  
Data were analyzed with the comparative threshold cycle (Ct) relative-quantification 
method. Relative gene expression was quantified as follows: fold change= 
2
−Δ(ΔCt)
 where ΔCt=Cttarget−Ctreference andΔ(ΔCt)=ΔCtsample−ΔCtcontrol. Ct is the fractional cycle 
number at which the fluorescence passes the fixed threshold. The target gene 
represents RYR1 gene, reference genes are  the hRPL27 and ACTB  gene in human 
and the GAPDH gene in mouse, "sample" refers to patient or heterozygous mice and "control" 
to control human or wild type mice. 
 
Production of human and mouse primary cultures 
Human satellite cells were produced from a muscle biopsy of a 25-year-old donor without 
neuromuscular disorder (CTRL cells) and from the biopsy of the patient (Y4864H cells). 
These cells were immortalized and cloned as previously described [20-21]. Primary cultures 
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of skeletal muscle from WT, RyR1
+/-
 and RyR1
-/-
 E19 mouse embryos were produced as 
described previously [22]. 
 
Cell Culture  
Immortalized human satellite cells or mouse satellite cells were amplified in proliferation 
medium composed of Ham's F-10 (Life technologies, Saint Aubin, France) supplemented 
with 20% FBS (Life technologies, Saint Aubin, France), 2% Ultroser G (Pall Biosepra, St 
Germain en Laye, France) and 2% Penicillin-Streptomycin (Life technologies, Saint Aubin, 
France). Differentiation into myotubes was induced by a shift to differentiation medium: 
DMEM (Life technologies, Saint Aubin, France) supplemented with 2% Heat Inactivated 
Horse Serum (Life technologies) and 1% Penicillin-Streptomycin. Human myotubes were 
cultured for seven to eight days and mouse myotubes for two to three days before intracellular 
calcium measurements. 
 
Intracellular Calcium Measurements 
Changes in intracellular calcium were evaluated using the calcium-dependent fluorescent dye 
Fluo-4 AM (Life Technologies, Saint Aubin, France), as described previously [23]. Calcium 
imaging was performed in Krebs buffer (136 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM 
MgCl2, 10 mM HEPES, pH 7.4, 6 mM D-Glucose). To obtain a calcium-free Krebs solution, 
CaCl2 was left out, while 1mM EGTA, 10 µM La
3+
, and 50 µM Cd
2+
 were added. 
Thapsigargin (Life technologies, Saint Aubin, France) was diluted at 1 µM in this medium 
and applied simultaneously with caffeine (40 mM) as described previously [24-25]. 4-chloro-
m-cresol (4-CmC) (Sigma-Aldrich) was diluted at 500 µM in Krebs buffer and 140 mM KCl 
solution was prepared in 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, pH 7.4 and 6 mM D-
Glucose. Fluorescence was measured by confocal laser scanning microscopy using a Leica 
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TCS-SPE microscope in the xyt mode. Changes in intracellular Ca
2+
 concentrations were 
presented as the ratio of fluorescence intensities with respect to the initial fluorescence 
intensity prior to drug addition (ΔF/F0). Data are given as mean ± SEM, and n represents the 
number of myotubes studied in each condition. 
 
Evaluation of muscle strength  
Muscle strength was evaluated in patients using manual muscle testing according to the 
Medical Research Council scale [26]. Muscle strength was evaluated in mice using a hang test 
as described previously [18]. Two months old male mice were positioned on a cross-wired 
surface turned upside down, and time before fall (up to 300s) was measured. 
 
Statistical Analysis 
Data were pooled over animals or cells within the same group and are presented as means ± 
SEM. Differences between CTRL and Y4864H cells were assessed using Student's t-test. 
Differences between WT, RyR1
+/- 
(He) cells, and RyR1
-/- 
(KO) cells were assessed using 
Student's t-test with Bonferroni correction for multiple comparison, and GraphPad Prism 6 
software, assuming significance at p < 0.05. 
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RESULTS 
Clinical and genetic reports  
The proband (Figure 1A, III:3) was a 28-year-old female who presented with a 
moderate muscle weakness since childhood, a slightly delayed motor development and a 
stable axial muscle deficiency. Muscle strength evaluation showed no distal deficiency, no 
reduction in cervical or hamstring muscles strength, a slight reduction in pectoralis major and 
deltoid muscles strength (level evaluated at 4/5), and a marked reduction in abdominal 
muscles strength (level evaluated at 2/5). Creatine kinase (CK) levels were normal (75 U/L, 
supplemental data, Table 1, III:3). A muscle biopsy demonstrated the presence of central 
cores using NADH staining and an in vitro contracture test (IVCT) indicated susceptibility to 
Malignant Hyperthermia (MHS) (supplemental data, Table 1, III:3) because of 
hypersensitivity of RyR1 to both caffeine and halotane. The genetic analysis performed on the 
mRNA extracted from the muscle biopsy identified the c.14590T>C; p.Tyr4864His variation 
at heterozygous state in the RYR1 gene, resulting in the substitution of the tyrosine in position 
4864 by a histidine (p.Y4864H) in the RyR1 protein. A diagnosis of CCD was proposed. 
The proband's father (Figure 1A, II:2) presented with a late onset moderate muscle 
weakness, and did not report any muscle weakness during childhood and adolescence. A 
clinical examination at age 60 demonstrated a mild quadriceps amyotrophy, right scapular 
winging and scoliosis. Muscle strength evaluation indicated a slight reduction in biceps, 
pectoralis major and hamstring muscles strength (evaluated at 4/5), and an important axial 
deficiency (abdominal muscles 2/5, cervical muscles 3/5). His CK levels were normal (168 
U/L, supplemental data, Table 1, II:2). Muscle biopsy displayed an aspect of congenital 
myopathy with the presence of atypical cores using NADH staining. He was also diagnosed as 
being susceptible to Malignant Hyperthermia (MHS) by IVCT (supplemental data, Table 1, 
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II:2), and a genetic analysis confirmed that he was carrying the same RYR1 heterozygous 
variant c. 14590T>C; p.Tyr4864His as his daughter. 
The patient’s uncle (II:1) who was tested MH Negative (MHN) by IVCT did not 
present with any clinical sign of myopathy and did not have the variant (Figure 1A and 
supplemental data Table 1). Therefore, the two individuals of the family carrying the 
p.Y4864H mutation were affected by a moderate CCD associated to MH, suggesting a 
dominant transmission.  
Using quantitative RT-PCR, the amount of RYR1 transcripts in the muscle of the 
proband (III.3) was evaluated at 52.6% ± 3.2% of the control muscle (Figure 1B), pointing to 
either the absence of transcript produced from one of the two RYR1 alleles or a reduction in 
both transcripts. The presence of the c.14590T>C variation at a heterozygous state in the 
mRNA transcripts detected by Sanger sequencing, suggested that most probably both 
transcripts were reduced. High Resolution Melting (HMR) analysis on cDNA of the patient 
confirmed that 2 transcripts were present in equivalent amount when amplifying a region 
encompassing the c.14590 position (data not shown). No other variation in the RyR1 mRNA 
was found to explain the global transcript reduction.  
Using quantitative Western blot, we determined that the amount of RyR1 present in 
the muscle of the proband (Ind. III.3) was 75.3 ± 6.4% (n=7) of the amount of RyR1 in a 
control muscle from a 25 years old female patient without any muscle disease (Figure 1B). To 
confirm that the amount of RyR1 in age-related control biopsies do not present similar 
variation and to validate our quantitative Western blot analysis, a quantitative Western blot 
was performed on four different 20-23 years-old non affected women, with normal physical 
activity (Figure 1C). The quantification of the amount of RyR1 compared to desmin in 11 
blots performed from these 4 controls result in a relative amount of RyR1 of 100% ± 6.3 %.  
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Consequences of the mutation 
To determine the physiological effects of the mutation, primary cultures were 
produced from the muscle biopsy of the patient, and were immortalized by double retroviral 
transduction using telomerase and Cdk4 [20-21]. Calcium imaging studies were performed on 
myotubes produced from the proband's immortalized cells (Y4864H cells) or from 
immortalized cells of a volunteer of 25 years with no muscle disease (CTRL cells), to assess 
their ability to release calcium after stimulation (Figure 2). In response to the membrane 
depolarization induced by addition of 140 mM KCl in presence of extracellular calcium, Ca
2+
 
release was significantly reduced in Y4864H myotubes (Figure 2A, white circles) compared 
to CTRL (Figure 2A, black circles) (p<0.0001). Similarly calcium release induced by a direct 
stimulation of RyR1 by 4-CmC (figure 2B) was also significantly decreased (p<0.0001). The 
amount of Ca
2+
 in the SR stores was evaluated after caffeine stimulation in presence of 
thapsigargin with or without extracellular calcium (Figure 2C and D). In all cases, the 
maximal amplitude of calcium released was significantly reduced in Y4864H myotubes 
compared to CTRL myotubes (Figure 2E, p<0.0001). The area under the curve (Figure 2F) 
reflecting the amount of calcium released was also significantly reduced except for the 
caffeine stimulation in presence of thapsigargin and extracellular calcium. The latter indicates 
that the reduction in the free SR calcium rapidly releasable upon stimulation could be 
compensated by an influx of external calcium (figure 2C). 
These results could be explained either i) by a reduction in the amount of calcium 
stored due to the p.Y4864H mutation leading to a "leaky" RyR1 channel, as usually observed 
with MH mutations leading to RyR1 hypersensitivity or ii) by defects in the RyR1-DHPR 
coupling leading to impaired calcium conductance [11-12], or iii) by the decreased quantity of 
RyR1 protein [17]. 
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RyR1 expression in RyR1
+/-
 heterozygous mice 
So far, the effect on calcium release of a small RyR1 protein decrease such as the one 
measured for the patient has not been evaluated. To test this effect, we used cells from 
heterozygous mice of a RyR1 KO model [27]. Muscle homogenates were prepared from WT 
and heterozygous RyR1
+/-
 mice to measure the amount of RyR1 transcript and protein. Only 
one allele of the RYR1 gene is expressed in RyR1
+/-
 heterozygous mice, and we first 
confirmed using quantitative RT-PCR that the mRNA of RyR1 was reduced by about 50% 
compared to WT (42.6% ± 7% for RyR1
+/-
 mice compared to 100% ± 4.8% for WT, n=3) 
(figure 3C). Using quantitative Western blot, the amount of RyR1 at the protein level detected 
in RyR1
+/-
 mice muscles was estimated to be 83.4 ± 2.6% of WT muscle (n = 9) (Figures 3A 
and B). 
These results showed that both the amount of RyR1 transcript and protein were 
decreased in RyR1
+/-
 heterozygous mice compared to WT mice, although to a lesser extent at 
the protein level. The relative protein amount of RyR1 measured in the patient with the 
p.Y4864H mutation compared to control (75.3 ± 6.4%, n=7) was not statistically different 
from the one found in RyR1
+/- 
mice compared to WT mice (83.4 ± 2.6%, n=9), and the 
relative amounts of transcript were also not different (52.6% ± 3.2%, n=12 in the patient and 
42.6% ± 7%, n=3 in the mouse). In both case, the alteration in the amount of RyR1 at the 
protein level is milder than the 50% lowering of transcription. Therefore the RyR1
+/-
 mouse 
line constitutes a good model to study the effect of such a RyR1 reduction.  
 
Measure of muscle strength in RyR1
+/-
 mice 
To evaluate the overall muscle performance of RyR1
+/-
 heterozygous mice, a hang test 
was performed. Two-month-old male mice were allowed to grip on a cross-wired surface 
placed upside down. Time spent hanging on the surface before fall was measured and no 
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significant difference was observed between WT (182 ± 43 s; n = 7) and RyR1
+/- 
(168 ± 36 s; 
n = 9) mice (supplementary data, Figure S1). This hang test thus showed that the decrease in 
RyR1 protein in RyR1
+/- 
mice did not modify muscle strength. 
 
Effect of RyR1 reduction on calcium fluxes 
To check whether the decrease in the quantity of RyR1 protein in RyR1
+/- 
mice induced 
defects on the calcium release, calcium imaging studies were performed on RyR1
+/+ 
(WT), 
RyR1
+/- 
(He) and RyR1
-/-
 (KO) myotubes (Figure 4). In agreement with some previous results 
[28] we observed that, compared to WT (Figures 4A and 4B, black circles) and He myotubes 
(Figures 4A and 4B, gray squares), the calcium release was greatly depressed in KO 
myotubes (Figure 4A and 4B, white circle) whether it be after a membrane depolarization 
(140mM KCl) or after a direct RyR1 stimulation (500µM 4-CmC). Both stimuli induced 
calcium release in WT myotubes (Figures 4A and 4B, black circles) and He myotubes 
(Figures 4A and 4B, gray squares). The amplitude of the peak in WT and He myotubes using 
RyR1 direct stimulation was similar (figure 4C). The peak was significantly increased in He 
compared to WT when KCl stimulation was used (figure 4C). These data demonstrated that 
the 16% decrease in RyR1 protein observed in He mice did not impair their ability to release 
calcium upon stimulation compared to the WT mice, consistent with the lack of muscle 
weakness observed during the hang test. 
 
DISCUSSION 
Functional studies of common dominant RYR1 mutations associated with CCD have 
suggested two main mechanisms responsible for a disturbed function of the mutant RyR1 
channel, namely either the presence of a leaky and hyperactive calcium channel associated 
with a reduction of SR calcium stores [13], or an "uncoupled" channel with reduced 
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permeability of RyR1 to Ca
2+
 [29]. In the present situation, the p.Y4864H mutation resulted in 
the presence of a calcium channel with altered properties which is associated with a reduction 
of the protein amount. A 50% reduction in the RyR1 mRNA in the patient biopsy was also 
observed, but the mechanisms leading to in this reduction in the RyR1 mRNA was not 
identified. In vitro calcium imaging showed that with all the stimulations used the amount of 
calcium released in Y4864H cells was significantly reduced. A reduction in the amplitude of 
the calcium store was observed using caffeine stimulation in the absence of external calcium 
influx and in the absence of calcium re-uptake in the sarcoplasmic reticulum (caffeine plus 
thapsigargin, Cd
2+ 
and La
3+
, figure 2D). This reduction in the amount of stored calcium, 
which could reflect a leaky calcium channel, was compensated by an influx of external 
calcium when present (caffeine stimulation in presence of thapsigargin with Ca
2+
, figure 2C), 
leading to equivalent amounts of calcium released in Y4864H cells compared to control cells 
(figure 2F). This reduction in the amount of stored calcium could account for the muscle 
weakness observed in the patient, but as it can be compensated in some conditions, it can only 
be a partial explanation. In order to identify another mechanism for the muscle weakness 
observed, we focused our studies on the impact of the reduction of RyR1 quantity. As RyR1 
deficiency has been proposed to result in disruption of EC coupling [17], we studied calcium 
release in a mouse model expressing a normal RyR1 but with a similar reduction in the 
amount of protein. This model was the heterozygous RyR1
+/- 
mouse line that has only one 
functional RYR1 allele. We first confirmed the presence of RyR1 transcript at about a 50% 
level of a WT mouse. Noticeably, the RyR1 protein level was higher, reaching 85% of a WT 
mouse, suggesting a post-transcriptional regulation of the protein amount, identical to the 
situation in observed in the patient. In the heterozygous mouse myotubes, no reduction in the 
amount of released calcium was observed either after KCl membrane depolarization 
mimicking EC coupling or after direct RyR1 stimulation by CmC. In addition, RyR1
+/-
 mice 
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showed no muscle weakness. Those results confirmed that this degree of RyR1 reduction was 
not sufficient to result in muscle weakness or to alter calcium release. Therefore, muscle 
weakness and alteration of calcium release observed in the patient expressing the p.Y4864H 
mutation is most probably not related to the reduction of RyR1 amount, but rather to the 
presence of mutant monomers into the tetrameric channel. As the mutation induced a 
reduction in the amount of calcium stored in the sarcoplasmic reticulum, and as this channel is 
most probably hyperactive as observed by the hypersensitivity evaluated in IVCT, it could be 
hypothesized that this mutation resulted in a hyperactive and leaky calcium channel. Calcium 
leak would explain the reduction in the stored calcium and muscle weakness, and the 
hyperactive channel would explain the increased sensitivity observed in IVCT leading to the 
MHS status of the patient. 
The 4864 position mapped within the last luminal loop of RyR1 monomer, which is involved 
in the selectivity pore for calcium permeation (P-loop), and is close to several other sites 
already found mutated in association with Central core Disease. A CCD family has previously 
been described with a mutation at the same position but leading to the substitution of tyrosine 
for cysteine instead of histidine (p.Y4864C) [30]. The affected patients of this family 
presented with a moderate myopathy, not associated to MH. Noteworthy, another mutation in 
position 4898 (p.I4898T), localized only 34 amino acids further away in the same intracellular 
loop, resulted in a severely uncoupled RyR1 [3]. It can therefore be postulated that the Y4864 
and the I4898 amino acids belong to different functional domains although they are in close 
vicinity along the primary sequence of RyR1. A steric inhibition in the movement of the 
luminal loop has been proposed as a consequence of the p.I4898T mutation, but due to a 
different outcome on muscle physiology, cannot account for the effect of p.Y4864H. Looking 
at the structure of RyR1 recently published [31, 32] (figure 5), these two residues are on both 
side of the so-called P-loop or pore-helix between transmembrane segments S5 and S6. 
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Because of the alteration of RyR1's channel function found in the patient one can hypothesize 
that the p.Y4864H mutation disrupts a binding site specific of a modulator of RyR1 function. 
Triadin could be such a modulator, as 3 amino acids in position 4878, 49707 and 49708 have 
been shown to be involved in the RyR-triadin interaction [33], D4878 being very close to 
Y4864. Nevertheless, mutation for Ala of this single Asp in position 4878 induced a slight 
reduction in the RyR-triadin binding, but no modification in the calcium release [34]. 
Therefore the effect of a mutation in position 4864 should most probably not be related to an 
alteration of the interaction RyR-triadin. Mutation on amino acid 4861 has also been 
frequently associated with CCD, often as a neo-mutation [35], with no or only a slight 
reduction in the amount of protein [35] and small alteration in calcium release (reduction in 
the amount of calcium stored, measured on immortalized B-cells, [36]). The effects of 
mutation in position 4861 are quite similar to those observed for mutation in position 4864, 
and a similar physiopathological mechanism could be hypothesized for mutations at these two 
positions.  
Overall, our study reports a CCD case where the effect of the RyR1 Y4864H mutation was 
explored. The reduction of total RyR1 mRNA in the patient muscle could not be explained 
but the fact that the amount of RyR1 protein was at 75% of a control suggested the presence 
of post transcriptional or epigenetic controls. This hypothesis is strengthened by the study of 
mRNA and protein in a RYR1 KO heterozygous mouse model, that shows the same level of 
RyR1 produced with a 50% reduction of mRNA. Our work also showed that the 
pathophysiological mechanisms linked to defects in calcium release in cells of the patient 
could not be attributed to a reduction in RyR1 protein levels, but rather to a direct effect of the 
p.Y4864H mutation on the channel properties. 
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Table 1 – Analysis of patients 
 
CK 
IVCT data 
 Hal 2% Caf 2mM 
III : 3 75 6N  5N  
II : 2 168 10N 6N  
II : 1 51 <2N <2N 
 
 
Table 1. CK levels and IVCT data of the proband (III.3) and two individuals from the family 
(II.2 and II.1). CK = Creatine Kinase activity is expressed in international units per liter 
(IU/L; normal < 205). IVCT = In Vitro Contracture Test. Hal = tension in Newton (N) at 2%  
halothane, the normal value being <2N. Caf = tension at 2 mM Caffeine, the normal value 
being <2N. 
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Figure legends 
 
Figure 1. Case description.  
(A). Pedigree of the family. Circles represent females and squares males. Filled symbols 
indicate affected individuals. The proband is indicated by the black arrow. Segregation of 
alleles is indicated below each individual. MH = Malignant Hyperthermia; MHN = MH 
Negative; MHS = MH Susceptible. (B). Quantitative analysis of RyR1 expression (protein 
and mRNA) in the skeletal muscle of the proband (Individual III.3). Twenty µg muscle 
homogenate from control (CTRL, lane 1) or proband (Y4864H, lane 2) were loaded on a 4-
15% polyacrylamide gel. The amount of RyR1 protein is expressed as the percentage of RyR1 
present in the control muscle, which relative expression compared to myosin was set at 100%. 
The central bars graph presents RyR1 protein mean amount ± SEM from seven different 
Western blots. The bar graph on the right is the Q-RT-PCR analysis of levels of RyR1 mRNA 
expressed as a percentage of control (which relative expression compared to reference genes 
was set to 100%). The data are presented as mean ± SEM of 9-12 different amplifications. ** 
p < 0.01, **** p<0.0001, Student's t-test. (C) Representative Western blot of different 
controls, 4 non affected women between 20 and 23 years. 
 
Figure 2. Calcium release in immortalized patient cells.  
Calcium imaging performed on control CTRL cells (black circle), and on patient’s Y4864H 
cells (white circle) differentiated for 7 to 8 days before calcium imaging. (A) Fluorescence 
variation curves induced by membrane depolarization (KCl 140 mM) applied during 60 s 
(black bar) in the presence of 2 mM external calcium, presented as mean (symbols) ± SEM. 
(B) Fluorescence variation curves induced by application of 4-Chloro-m-Cresol (CmC) 
500 µM during 60 s (black bar) in the presence of 2 mM external calcium, presented as mean 
(symbols) ± SEM. (C) Fluorescence variation curves induced by application of caffeine 
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40 mM plus thapsigargin 1µM (Caf + Thapsigargin) during 60 s (black bar) in the presence of 
2 mM external calcium, presented as mean (symbols) ± SEM . (D) Fluorescence variation 
curves induced by application of caffeine 40mM plus thapsigargin 1µM in absence of 
extracellular calcium (Caf + Thapsigargin - Ca
2+
) during 60 s (black bar) in the presence of 
Cd
2+
 and La
3+
, presented as mean (symbols) ± SEM . (E) The maximal amplitude of the peak 
for each curve is presented in the bar plots, with the number of myotubes analyzed in each 
bar. **** p<0.0001, Student's t test comparisons between CTRL and Y4864H cells, for each 
stimulation. (F) The area under each curve (A.U.) has been calculated for each stimulation, in 
control myotubes (black bars) and Y4864H myotubes (white bars) and is presented as mean ± 
SEM of the number of myotubes indicated in each bar. Statistics : Student's t-test of Y4864H 
myotubes compared to control myotubes **** p < 0.0001, *** p<0.001, ns: non significant. 
 
Figure 3. Expression of RyR1 in heterozygous RyR1
+/-
 mouse muscles 
(A) Quantitative Western blot analysis of RyR1 expression in skeletal muscle homogenates 
from WT mice (WT) or from heterozygous RyR1
+/-
 mice (He). (B) The relative amount of 
RyR1 at the protein level compared to myosin was set to 100% in WT mice. The amount of 
RyR1 in He mice is presented as mean ± SEM of 9 experiments performed in 3 different 
mice. *** p < 0.001 Student's t-test between WT and He. (C) Q-RT-PCR analysis of levels of 
RyR1 mRNA expressed as a percentage of WT mice (which relative expression compared to 
GAPDH was set to 100%). The data are presented as mean ±SEM of 3 different mice. ** p < 
0.01 Student's t-test between WT and He. 
 
Figure 4. Calcium release in mouse cells. 
Calcium imaging performed on WT satellites cells (black circle), on RyR1
+/-
 heterozygous 
mouse cells (gray square) and on RyR1
-/-
 KO mouse cells (white circle) differentiated for 2 to 
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3 days before calcium imaging. (A) Fluorescence variation curves induced by membrane 
depolarization (KCl 140 mM) applied during 40 s (black bar) in the presence of 2 mM 
external calcium, presented as mean (symbols) ± SEM. (B) Fluorescence variation curves 
induced by application of 4-Chloro-m-Cresol (CmC) 500 µM during 40 s (black bar) in the 
presence of 2 mM external calcium, presented as mean (symbols) ± SEM. (C) The maximal 
amplitude of the peak for each curve is presented in the bar plots, with the number of 
myotubes analyzed in each bar. **** p<0.0001, Student's t test followed by Bonferroni 
correction for multiple comparison, compared to WT. (D) The area under each curve (A.U.) 
has been calculated for each stimulation, in WT myotubes (black bars), He myotubes (gray 
bars) and KO myotubes (white bars) and is presented as the mean ± SEM of the number of 
myotubes indicated in each bar. **** p<0.0001, Student's t test followed by Bonferroni 
correction for multiple comparison, compared to WT. 
 
Figure 5. Localization of the mutation in the structure of the protein  
The localization of the mutation presented in this study, p.Y4864H, as well as two close 
amino acids R4864 and I4898 both involved in CCD, are reported on the structure of RyR1 
recently proposed from single particle electron cryomicroscopy [31, 32]. These amino acids 
are in the luminal loop between transmembrane helixes S5 and S6, which contain the pore 
helix (P-helix) involved in pore formation. 
   
 
31 
 
Figure 1 
 
 
 
   
 
32 
 
Figure 2 
 
 
   
 
33 
 
Figure 3 
 
 
 
 
   
 
34 
 
Figure 4 
 
   
 
35 
 
Figure 5 
 
   
 
36 
 
Supplementary data 
 
T
im
e
 (
s
)
W T H E
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
n s
 
Figure S1. Hang test performed on 7 wild type (WT) and 9 RyR1
+/-
 heterozygous (HE) 2-
month-old male mice. Mean grip time for WT mice was 182 ± 43 s and for RyR1
+/-
 
heterozygous mice 168 ± 36 s. Mean weight: 30.0 ± 0.4 g, no significant difference in weight 
between WT and He mice. ns: non significant Student's t-test. 
